Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Gina M. Mantia-Smaldone, Bradley Corr & Christina S. Chu. (2012) Immunotherapy in ovarian cancer. Human Vaccines & Immunotherapeutics 8:9, pages 1179-1191.
Read now
Read now
Jenny M Whitworth & Ronald D Alvarez. (2011) Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature. Expert Opinion on Biological Therapy 11:6, pages 751-762.
Read now
Read now
Articles from other publishers (50)
Cancan Duan, KuoKuo Li, Xiaohua Pan, Zhaolian Wei & Lan Xiao. (2023) Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center. BMC Cancer 23:1.
Crossref
Crossref
Dongyu Huang, Runzhi Wang, Lewei Tian & Hui Wang. (2023) Integrated bioinformatics and experimental validation reveal the role of JARID2 in ovarian cancer. Epigenomics 15:8, pages 487-505.
Crossref
Crossref
Samir A. Farghaly. 2022. Advances in Diagnosis and Management of Ovarian Cancer. Advances in Diagnosis and Management of Ovarian Cancer
179
203
.
Jaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, David Barras, Isaac Crespo, Alizée J. Grimm, Julia Casado, Raphael Genolet, Fabrizio Benedetti, Alexandre Wicky, Kalliopi Ioannidou, Wilson Castro, Christopher Neal, Amandine Moriot, Stéphanie Renaud-Tissot, Victor Anstett, Noémie Fahr, Janos L. Tanyi, Monika A. Eiva, Connor A. Jacobson, Kathleen T. Montone, Marie Christine Wulff Westergaard, Inge Marie Svane, Lana E. Kandalaft, Mauro Delorenzi, Peter K. Sorger, Anniina Färkkilä, Olivier Michielin, Vincent Zoete, Santiago J. Carmona, Periklis G. Foukas, Daniel J. PowellJr.Jr., Sylvie Rusakiewicz, Marie-Agnès Doucey, Denarda Dangaj Laniti & George Coukos. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39:12, pages 1623-1642.e20.
Crossref
Crossref
Brittany P. Rickard, Christina Conrad, Aaron J. Sorrin, Mustafa Kemal Ruhi, Jocelyn C. Reader, Stephanie A. Huang, Walfre Franco, Giuliano Scarcelli, William J. Polacheck, Dana M. Roque, Marcela G. del Carmen, Huang-Chiao Huang, Utkan Demirci & Imran Rizvi. (2021) Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers 13:17, pages 4318.
Crossref
Crossref
Alejandra Martinez, Jean-Pierre Delord, Maha Ayyoub & Christel Devaud. (2020) Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers 12:7, pages 1761.
Crossref
Crossref
Dmitriy Zamarin, Sven Walderich, Aliya Holland, Qin Zhou, Alexia E Iasonos, Jean M Torrisi, Taha Merghoub, Lewis F Chesebrough, Autumn S Mcdonnell, Jacqueline M Gallagher, Yanyun Li, Travis J Hollmann, Rachel N Grisham, Courtney L Erskine, Mathew S Block, Keith L Knutson, Roisin E O’Cearbhaill, Carol Aghajanian & Jason A Konner. (2020) Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal for ImmunoTherapy of Cancer 8:1, pages e000829.
Crossref
Crossref
Logan Corey, Ana Valente & Katrina Wade. (2020) Personalized Medicine in Gynecologic Cancer. Surgical Oncology Clinics of North America 29:1, pages 105-113.
Crossref
Crossref
Jianying Guo, Xiao Li, Wenhao Zhang, Yuling Chen, Songbiao Zhu, Liang Chen, Renhua Xu, Yang Lv, Di Wu, Mingzhou Guo, Xiaohui Liu, Weiguo Lu & Haiteng Deng. (2019) HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer. Scientific Reports 9:1.
Crossref
Crossref
Logan Corey, Ana Valente & Katrina Wade. (2019) Personalized Medicine in Gynecologic Cancer. Obstetrics and Gynecology Clinics of North America 46:1, pages 155-163.
Crossref
Crossref
Alain Piché. (2018) Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression: Impact and significance. World Journal of Clinical Oncology 9:8, pages 167-171.
Crossref
Crossref
Chien-Fu Hung, Xuequn Xu, Linhong Li, Ying Ma, Qiu Jin, Angelia Viley, Cornell Allen, Pachai Natarajan, Rama Shivakumar, Madhusudan V. Peshwa & Leisha A. Emens. (2018) Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Human Gene Therapy 29:5, pages 614-625.
Crossref
Crossref
Venkatesh Krishnan, Jonathan S. Berek & Oliver Dorigo. (2017) Immunotherapy in ovarian cancer. Current Problems in Cancer 41:1, pages 48-63.
Crossref
Crossref
Amani Makkouk, Cariad Chester & Holbrook E. Kohrt. 2017. Ovarian Cancers. Ovarian Cancers
143
168
.
Eric T. Alexander, Allyson R. Minton, Molly C. Peters, Joanne van Ryn & Susan K. Gilmour. (2016) Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment. Oncotarget 7:51, pages 85291-85305.
Crossref
Crossref
Hong Qu, Yuling Chen, Guangming Cao, Chongdong Liu, Jiatong Xu, Haiteng Deng & Zhenyu Zhang. (2016) Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics. Oncotarget 7:50, pages 83187-83199.
Crossref
Crossref
Irina V. Tiper, Sarah M. Temkin, Sarah Spiegel, Simeon E. Goldblum, Robert L. GiuntoliIIII, Mathias Oelke, Jonathan P. Schneck & Tonya J. Webb. (2016) VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clinical Cancer Research 22:16, pages 4249-4258.
Crossref
Crossref
Dmitriy Zamarin & Amir A. Jazaeri. (2016) Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic Oncology 141:1, pages 86-94.
Crossref
Crossref
Cariad Chester, Oliver Dorigo, Jonathan S Berek & Holbrook Kohrt. (2015) Immunotherapeutic approaches to ovarian cancer treatment. Journal for ImmunoTherapy of Cancer 3:1.
Crossref
Crossref
Mythili Koneru, Roisin O’Cearbhaill, Swati Pendharkar, David R Spriggs & Renier J Brentjens. (2015) A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. Journal of Translational Medicine 13:1.
Crossref
Crossref
Jacek R. Wilczyński & Marek Nowak. 2015. Cancer Immunology. Cancer Immunology
413
456
.
Khaled A. Ahmad & Ahmed Abdrabou. (2014) The significance of added ADC value to conventional MR imaging in differentiation between benign and malignant ovarian neoplasms. The Egyptian Journal of Radiology and Nuclear Medicine 45:3, pages 997-1002.
Crossref
Crossref
Yousef Zakharia, Osama Rahma & Samir N. Khleif. (2014) Ovarian Cancer from an Immune Perspective. Radiation Research 182:2, pages 239-251.
Crossref
Crossref
BASKAR SUBRAMANI, CHITHRA RAMANATHAN PULLAI, KOHILA KRISHNAN, SHEELA DEVI SUGADAN, XUEWEN DENG, TERUNUMA HIROSHI & KANANATHAN RATNAVELU. (2014) Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients. Biomedical Reports 2:4, pages 505-508.
Crossref
Crossref
Samir A. Farghaly. 2014. Advances in Diagnosis and Management of Ovarian Cancer. Advances in Diagnosis and Management of Ovarian Cancer
199
222
.
Lana E. Kandalaft, Klara Balint, Jonathan S. Berek & George Coukos. 2014. Controversies in the Management of Gynecological Cancers. Controversies in the Management of Gynecological Cancers
323
337
.
Jaikumar Duraiswamy, Gordon J. Freeman & George Coukos. (2013) Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer. Cancer Research 73:23, pages 6900-6912.
Crossref
Crossref
Cheryl Lai-Lai Chiang, Lana E. Kandalaft, Janos Tanyi, Andrea R. Hagemann, Gregory T. Motz, Nikolaos Svoronos, Kathleen Montone, Gina M. Mantia-Smaldone, Lori Smith, Harvey L. Nisenbaum, Bruce L. Levine, Michael Kalos, Brian J. Czerniecki, Drew A. Torigian, Daniel J. PowellJrJr, Rosemarie Mick & George Coukos. (2013) A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research 19:17, pages 4801-4815.
Crossref
Crossref
Lana E Kandalaft, Cheryl L Chiang, Janos Tanyi, Greg Motz, Klara Balint, Rosemarie Mick & George Coukos. (2013) A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine 11:1, pages 149.
Crossref
Crossref
Premal H. Thaker & Anil K. Sood. 2013. Comprehensive Gynecology. Comprehensive Gynecology
623
633
.
Lana E Kandalaft, Daniel J PowellJrJr & George Coukos. (2012) A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of Translational Medicine 10:1.
Crossref
Crossref
Brad H. Nelson. (2012) Killer T cells to the rescue in ovarian cancer. Gynecologic Oncology 124:2, pages 178-179.
Crossref
Crossref
Min Cheng, Juan Ma, Yongyan Chen, Jianhua Zhang, Weidong Zhao, Jian Zhang, Haiming Wei, Bin Ling, Rui Sun & Zhigang Tian. (2011) Establishment, Characterization, and Successful Adaptive Therapy against Human Tumors of NKG Cell, a New Human NK Cell Line. Cell Transplantation 20:11-12, pages 1731-1746.
Crossref
Crossref
Lukasz Wicherek, Wojciech Jozwicki, Wieslawa Windorbska, Krzysztof Roszkowski, Ewelina Lukaszewska, Michal Wisniewski, Anna Aneta Brozyna, Pawel Basta, Joanna Skret-Magierlo, Krzysztof Koper, Wojciech Rokita & Magdalena Dutsch-Wicherek. (2011) Analysis of Treg Cell Population Alterations in the Peripheral Blood of Patients Treated Surgically for Ovarian Cancer - A Preliminary Report. American Journal of Reproductive Immunology 66:5, pages 444-450.
Crossref
Crossref
Lana E. KandalaftDaniel J. PowellJrJrNathan SinghGeorge Coukos. (2011) Immunotherapy for Ovarian Cancer: What's Next?. Journal of Clinical Oncology 29:7, pages 925-933.
Crossref
Crossref
Kazuhiko Ino. (2011) Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Current Opinion in Obstetrics & Gynecology 23:1, pages 13-18.
Crossref
Crossref
Lana E. Kandalaft & George Coukos. 2011. Immunologic Signatures of Rejection. Immunologic Signatures of Rejection
211
228
.
Eric Tran, Julie S. Nielsen, Darin A. Wick, Alvin V. Ng, Lisa D. S. Johnson, Nancy J. Nesslinger, Elissa McMurtrie, John R. Webb & Brad H. Nelson. (2010) Polyfunctional T-Cell Responses Are Disrupted by the Ovarian Cancer Ascites Environment and Only Partially Restored by Clinically Relevant Cytokines. PLoS ONE 5:12, pages e15625.
Crossref
Crossref
Bei Liu, John Nash, Carolyn Runowicz, Helen Swede, Richard Stevens & Zihai Li. (2010) Ovarian cancer immunotherapy: opportunities, progresses and challenges. Journal of Hematology & Oncology 3:1.
Crossref
Crossref
Irina Nazarenko, Marcel Jenny, Jana Keil, Cornelia Gieseler, Karen Weisshaupt, Jalid Sehouli, Stefan Legewie, Lena Herbst, Wilko Weichert, Silvia Darb-Esfahani, Manfred Dietel, Reinhold Schäfer, Florian Ueberall & Christine Sers. (2010) Atypical Protein Kinase C ζ Exhibits a Proapoptotic Function in Ovarian Cancer. Molecular Cancer Research 8:6, pages 919-934.
Crossref
Crossref
K Anwer, M N Barnes, J Fewell, D H Lewis & R D Alvarez. (2009) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Therapy 17:3, pages 360-369.
Crossref
Crossref
Lana E. Kandalaft, Nathan Singh, John B. Liao, Andrea Facciabene, Jonathan S. Berek, Daniel J. PowellJr.Jr. & George Coukos. (2010) The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology 116:2, pages 222-233.
Crossref
Crossref
Nikos G. Gavalas, Alexandra Karadimou, Meletios A. Dimopoulos & Aristotelis Bamias. (2010) Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization. Clinical and Developmental Immunology 2010, pages 1-15.
Crossref
Crossref
Ioannis Alagkiozidis, Andrea Facciabene, Carmine Carpenito, Fabian Benencia, Zdenka Jonak, Sarah Adams, Richard G Carroll, Phyllis A Gimotty, Rachel Hammond, Gwen-äel Danet-Desnoyers, Carl H June, Daniel J PowellJrJr & George Coukos. (2009) Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. Journal of Translational Medicine 7:1.
Crossref
Crossref
Emily K. Mader, Yoshihiro Maeyama, Yi Lin, Greg W. Butler, Holly M. Russell, Evanthia Galanis, Stephen J. Russell, Allan B. Dietz & Kah-Whye Peng. (2009) Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model. Clinical Cancer Research 15:23, pages 7246-7255.
Crossref
Crossref
Sarah F. Adams, Douglas A. Levine, Mark G. Cadungog, Rachel Hammond, Andrea Facciabene, Narciso Olvera, Stephen C. Rubin, Jeff Boyd, Phyllis A. Gimotty & George Coukos. (2009) Intraepithelial T cells and tumor proliferation. Cancer 115:13, pages 2891-2902.
Crossref
Crossref
Jun Dou, Yongfang Wang, Jing Wang, Fengshu Zhao, Yating Li, Minggang Cao, Weihua Hu, Kai Hu, Xiang Feng He, Lili Chu, Chuilian Jiang & Ning Gu. (2009) Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model. Immunobiology 214:6, pages 483-492.
Crossref
Crossref
Claudia Jursik, Michaela Prchal, Regina Grillari-Voglauer, Karel Drbal, Elke Fuertbauer, Herbert Jungfer, Winfried H. Albert, Eva Steinhuber, Thomas Hemetsberger, Johannes Grillari, Hannes Stockinger & Hermann Katinger. (2009) Large-Scale Production and Characterization of Novel CD4+ Cytotoxic T Cells with Broad Tumor Specificity for Immunotherapy. Molecular Cancer Research 7:3, pages 339-353.
Crossref
Crossref
Maurie Markman. (2008) Issues in the Design of Ovarian Cancer Trials Evaluating Antineoplastic Agents Not Predicted to Cause Regression of Existing Tumor Masses. Clinical Ovarian Cancer 1:2, pages 111-115.
Crossref
Crossref
Tonya J. Webb, Robert L. GiuntoliIIII, Ophelia Rogers, Jonathan Schneck & Mathias Oelke. (2008) Ascites Specific Inhibition of CD1d-Mediated Activation of Natural Killer T Cells. Clinical Cancer Research 14:23, pages 7652-7658.
Crossref
Crossref